Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magnesium Supplementation in XMEN Syndrome
NCT02496676Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- May 2016
- Primary completion
- Apr 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of Magnesium L-threonate in X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection and neoplasia (XMEN), sponsored by National Institute of Allergy and Infectious Diseases. Started May 2016; status: completed.
02
Drugs
Magnesium L-threonate
03
Conditions
X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection and neoplasia (XMEN)
Beyond the preview
Go deeper on NCT02496676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02496676.